Effects of CYP2C9*1/*13 on the pharmacokinetics and pharmacodynamics of meloxicam

British Journal of Clinical Pharmacology

Volumn 71, Issue 4, 2011, Pages 550-555

  Bae, Jung Woo ^a   Choi, Chang Ik ^a   Jang, Choon Gon ^a   Lee, Seok Yong ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

CYP2C9; Genetic polymorphism; Meloxicam; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 2C9; MELOXICAM; THROMBOXANE B2; CYP2C9 PROTEIN, HUMAN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

AREA UNDER THE CURVE; ARTICLE; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; GENE AMPLIFICATION; GENE SEQUENCE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; ULTRAVIOLET RADIATION; ADULT; ASIAN; GENETIC POLYMORPHISM; GENETICS; METABOLIC CLEARANCE RATE; SOUTH KOREA;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CYCLOOXYGENASE INHIBITORS; HUMANS; MALE; METABOLIC CLEARANCE RATE; POLYMORPHISM, GENETIC; REPUBLIC OF KOREA; THIAZINES; THIAZOLES; YOUNG ADULT;

EID: 79952605178     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03853.x     Document Type: Article

References (35)

1. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995; 44: 423-33.
2. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S, Kummer M. Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 1995; 23: 1206-13.
3. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E, Sauter T. Metabolism of Meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998; 28: 1-13.
4. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-63. Erratum in: Pharmacogenetics 2002; 12: 343.
5. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
6. Ingelman-Sundberg M, Daly AK, Nebe DW, eds. Human Cytochrome P450(CYP) Allele Nomenclature Committee Website. Available at (last accessed 1 March 2010).
7. Xie HG, Prasad HC, Kim RB, Stein CM. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev 2002; 54: 1257-70.
8. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol 2001; 52: 349-55.
9. Si D, Guo Y, Zhang Y, Yang L, Zhou H, Zhong D. Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 2004; 14: 465-9.
10. Bae JW, Kim HK, Kim JH, Yang SI, Kim MJ, Jang CG, Lee SY. Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 2005; 60: 418-22.
11. Maekawa K, Harakawa N, Sugiyama E, Tohkin M, Kim SR, Kaniwa N, Katori N, Hasegawa R, Yasuda K, Kamide K, Miyata T, Saito Y, Sawada J. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects. Drug Metab Dispos 2009; 37: 1895-903.
12. Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11: 781-91.
13. *13) in the metabolism of lornoxicam in humans. Drug Metab Dispos 2005; 33: 749-53.
14. *13. Xenobiotica 2005; 35: 853-61.
15. *13 allele on the pharmacokinetics of losartan in healthy male subjects. Xenobiotica 2009; 39: 788-93.
16. *13 variant activity reduction: a molecular dynamics simulation and docking study. Biochimie 2006; 88: 1457-65.
17. Kim HS, Lee SS, Oh M, Jang YJ, Kim EY, Han IY, Cho KH, Shin JG. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenet Genomics 2009; 19: 103-12.
18. Maekawa K, Fukushima-Uesaka H, Tohkin M, Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N, Suzuki K, Yanagawa T, Saito Y, Sawada J. Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics 2006; 16: 497-514.
19. Bae JW, Kim MJ, Jang CG, Lee SY. Determination of meloxicam in human plasma using a HPLC method with UV detection and its application to a pharmacokinetic study. J Chromatogr B 2007; 859: 69-73.
20. 2 production in healthy subjects. Thromb Res 1980; 17: 317-27.
21. Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19: 589-601.
22. Brogden RN, Heel RC, Speight TM, Avery GS. Piroxicam. A reappraisal of its pharmacology and therapeutic efficacy. Drugs 1984; 28: 292-323.
23. Polli JE, Bigora S, Piscitelli DA, Straughn AB, Young D. 'Pavlovian' food effect on the enterohepatic recirculation of piroxicam. Biopharm Drug Dispos 1996; 17: 635-41.
24. Turck D, Roth W, Busch U. A review of the clinical pharmacokinetics of meloxicam. Br J Rheumatol 1996; 35: (Suppl. 1): 13-6.
25. Turck D, Busch U, Heinzel G, Narjes H. Clinical pharmacokinetics of meloxicam. Arzneimittelforschung 1997; 47: 253-8.
26. Rani S, Guttikar S, Rathod R, Cherian B, Nivsarkar M, Padh H. Determination of oral meloxicam pharmacokinetics parameters in Asian Indians: comparison with a German population. Saudi Pharm J 2004; 12: 144-9.
27. Medvedovici A, Albu F, Georgita C, Mircioiu C, David V. A non-extracting procedure for the determination of meloxicam in plasma samples by HPLC-diode array detection. Arzneimittelforschung 2005; 55: 326-31.
28. Busch U, Heinzel G, Narjes H. The effect of cholestyramine on the pharmacokinetics of meloxicam, a new non-steroidal anti-inflammatory drug (NSAID), in man. Eur J Clin Pharmacol 1995; 48: 269-72.
29. Engelhardt G, Bogel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings. Biochem Pharmacol 1996; 51: 21-8.
30. Engelhardt G, Bogel R, Schnitzer C, Utzmann R. Meloxicam: influence on arachidonic acid metabolism. Part II. In vivo findings. Biochem Pharmacol 1996; 51: 29-38.
31. Ogino K, Hatanaka K, Kawamura M, Katori M, Harada Y. Evaluation of pharmacological profile of meloxicam as an anti-inflammatory agent, with particular reference to its relative selectivity for cyclooxygenase-2 over cyclooxygenase-1. Pharmacology 1997; 55: 44-53.
32. Tegeder I, Lotsch J, Krebs S, Muth-Selbach U, Brune K, Geisslinger G. Comparison of inhibitory effects of meloxicam and diclofenac on human thromboxane biosynthesis after single doses and at steady state. Clin Pharmacol Ther 1999; 65: 533-44.
33. Odani A, Hashimoto Y, Otsuki Y, Uwai Y, Hattori H, Furusho K, Inui K. Genetic polymorphism of the CYP2C subfamily and its effect on the pharmacokinetics of phenytoin in Japanese patients with epilepsy. Clin Pharmacol Ther 1997; 62: 287-92.
34. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 2001; 11: 803-8.
35. Allabi AC, Gala JL, Horsmans Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet Genomics 2005; 15: 779-86.